Nash, the one-time favourite therapy area for biopharma speculators, is back.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
Novo Nordisk's cell therapy collaborations are a sign that serious work is under way.
Big cap medtech is hiring, largely thanks to organic growth.
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
Big pharma is using machine learning to improve the drug development process – but can the tech live up to the hype?
The amyloid hypothesis of Alzheimer's has taken another battering – and some companies are finally taking a new approach.
Sequencing data is all well and good, but what does it mean?
Drug price inflation has slowed to crawl, but political pressure can only keep a lid on costs for so long.